MX2012013703A - Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih). - Google Patents
Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).Info
- Publication number
- MX2012013703A MX2012013703A MX2012013703A MX2012013703A MX2012013703A MX 2012013703 A MX2012013703 A MX 2012013703A MX 2012013703 A MX2012013703 A MX 2012013703A MX 2012013703 A MX2012013703 A MX 2012013703A MX 2012013703 A MX2012013703 A MX 2012013703A
- Authority
- MX
- Mexico
- Prior art keywords
- modified
- betulinic acid
- maturation inhibitors
- acid derivatives
- hiv maturation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se definen compuestos que tienen propiedades farmacológicas y bioafección, sus composiciones farmacéuticas y métodos de uso. En particular, ácido C3-betulínico modificado y otros derivados de productos naturales relacionados estructuralmente que poseen una actividad antiviral única se proporcionan como inhibidores de la maduración del VIH. Estos compuestos son útiles para el tratamiento del VIH y el SIDA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35133810P | 2010-06-04 | 2010-06-04 | |
PCT/US2011/038879 WO2011153315A1 (en) | 2010-06-04 | 2011-06-02 | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012013703A true MX2012013703A (es) | 2012-12-17 |
Family
ID=44627236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012013703A MX2012013703A (es) | 2010-06-04 | 2011-06-02 | Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih). |
Country Status (12)
Country | Link |
---|---|
US (1) | US8754068B2 (es) |
EP (1) | EP2576585B8 (es) |
JP (1) | JP5752789B2 (es) |
CN (1) | CN103038245B (es) |
AR (1) | AR081637A1 (es) |
BR (1) | BR112012030818A2 (es) |
CA (1) | CA2801487C (es) |
EA (1) | EA022393B1 (es) |
ES (1) | ES2612452T3 (es) |
MX (1) | MX2012013703A (es) |
TW (1) | TW201201793A (es) |
WO (1) | WO2011153315A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146768A1 (en) | 2010-05-20 | 2011-11-24 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
MX2013008359A (es) * | 2011-01-31 | 2013-08-27 | Bristol Myers Squibb Co | Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana. |
CA2826113C (en) * | 2011-01-31 | 2018-09-04 | Bristol-Myers Squibb Company | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
CN104080454B (zh) | 2011-06-06 | 2017-02-15 | 爱荷华大学研究基金会 | 用于抑制肌萎缩的方法 |
US8754069B2 (en) | 2011-09-21 | 2014-06-17 | Bristol-Myers Squibb Company | Betulinic acid derivatives with antiviral activity |
US8906889B2 (en) * | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
WO2014105926A1 (en) | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Novel betulinic acid proline derivatives as hiv inhibitors |
KR20150115881A (ko) * | 2013-02-06 | 2015-10-14 | 브리스톨-마이어스 스큅 컴퍼니 | Hiv 성숙 억제 활성을 갖는 c-19 변형된 트리테르페노이드 |
US9249180B2 (en) * | 2013-02-25 | 2016-02-02 | Bristol-Myers Squibb Company | C-3 alkyl and alkenyl modified betulinic acid derivatives |
WO2015157483A1 (en) | 2014-04-11 | 2015-10-15 | Bristol-Myers Squibb Company | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
WO2015195776A1 (en) | 2014-06-19 | 2015-12-23 | Bristol-Myers Squibb Company | Betulinic acid derivatives with hiv maturation inhibitory activity |
US20170129916A1 (en) | 2014-06-26 | 2017-05-11 | Hetero Research Foundation | Novel betulinic proline imidazole derivatives as hiv inhibitors |
CA2967679A1 (en) * | 2014-11-14 | 2016-05-19 | VIIV Healthcare UK (No.5) Limited | Oxolupene derivatives |
US9914747B2 (en) | 2014-11-14 | 2018-03-13 | VIIV Healthcare UK (No.5) Limited | Extended betulinic acid analogs |
JP2017533934A (ja) | 2014-11-14 | 2017-11-16 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | C17アリール置換ベツリン酸類似体 |
MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
US10370405B2 (en) | 2015-03-16 | 2019-08-06 | Hetero Labs Limited | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors |
KR20180028534A (ko) | 2015-07-28 | 2018-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체 |
EP3328875A1 (en) | 2015-07-28 | 2018-06-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Betuin derivatives for preventing or treating hiv infections |
WO2017051355A1 (en) | 2015-09-24 | 2017-03-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds with hiv maturation inhibitory activity |
US20190023733A1 (en) | 2016-01-20 | 2019-01-24 | Glaxosmithkline Intellectual Property (No.2) Limited | Amine derivatives of lupanes with hiv maturation inhibitory activity |
AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
EP3478661A1 (en) * | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Aza-substituted inhibitors of human immunodeficiency virus replication |
WO2018002849A1 (en) * | 2016-06-30 | 2018-01-04 | VIIV Healthcare UK (No.5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
WO2018002848A1 (en) * | 2016-06-30 | 2018-01-04 | VIIV Healthcare UK (No.5) Limited | Azadecalin derivatives as inhibitors of human immunodeficiency virus replication |
JP7436385B2 (ja) | 2018-04-24 | 2024-02-21 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | Hiv成熟阻害活性を有する化合物 |
PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
US5679828A (en) * | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
PT1068219E (pt) | 1998-03-02 | 2007-03-30 | Univ North Carolina | Derivados acilados de betulina e de di-hidrobetulina, sua preparação e sua utilização |
US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
CA2499038A1 (en) * | 2002-09-26 | 2004-04-08 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
ES2319653T3 (es) * | 2003-02-11 | 2009-05-11 | Novelix Pharmaceuticals, Inc. | Medicamento para la inhibicion del crecimiento de tumores. |
US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
WO2005090380A1 (en) * | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceuticals salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid |
WO2005112929A2 (en) * | 2004-05-20 | 2005-12-01 | Cornell Research Foundation, Inc. | Anti-hiv-1 activity of betulinol derivatives |
TW200628161A (en) * | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
JP2009527563A (ja) * | 2006-02-21 | 2009-07-30 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ウイルス感染症を治療するのに有用な置換タラキサスタン |
WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
WO2009020732A1 (en) * | 2007-08-03 | 2009-02-12 | Advanced Life Sciences, Inc. | Lupane-type triterpenoids modified at 30-position and analogues thereof |
WO2009042166A1 (en) | 2007-09-25 | 2009-04-02 | Panacos Pharmaceuticals, Inc. | Liquid bevirimat dosage forms for oral administration |
EP2257567A1 (en) | 2008-02-14 | 2010-12-08 | Virochem Pharma Inc. | Novel 17 beta lupane derivatives |
WO2009114083A2 (en) | 2008-03-03 | 2009-09-17 | Panacos Pharmaceuticals, Inc. | Determinants of antiviral response |
WO2009129548A1 (en) * | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
CN102883608A (zh) * | 2010-02-11 | 2013-01-16 | 葛兰素史密丝克莱恩有限责任公司 | 白桦脂醇衍生物 |
-
2011
- 2011-06-02 MX MX2012013703A patent/MX2012013703A/es active IP Right Grant
- 2011-06-02 CA CA2801487A patent/CA2801487C/en not_active Expired - Fee Related
- 2011-06-02 US US13/151,706 patent/US8754068B2/en not_active Expired - Fee Related
- 2011-06-02 CN CN201180038211.9A patent/CN103038245B/zh not_active Expired - Fee Related
- 2011-06-02 WO PCT/US2011/038879 patent/WO2011153315A1/en active Application Filing
- 2011-06-02 BR BR112012030818A patent/BR112012030818A2/pt not_active IP Right Cessation
- 2011-06-02 JP JP2013513339A patent/JP5752789B2/ja not_active Expired - Fee Related
- 2011-06-02 EA EA201270780A patent/EA022393B1/ru not_active IP Right Cessation
- 2011-06-02 EP EP11726563.7A patent/EP2576585B8/en not_active Not-in-force
- 2011-06-02 ES ES11726563.7T patent/ES2612452T3/es active Active
- 2011-06-03 AR ARP110101944A patent/AR081637A1/es not_active Application Discontinuation
- 2011-06-03 TW TW100119644A patent/TW201201793A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2801487C (en) | 2017-12-05 |
EP2576585B1 (en) | 2016-10-12 |
US8754068B2 (en) | 2014-06-17 |
EP2576585A1 (en) | 2013-04-10 |
JP5752789B2 (ja) | 2015-07-22 |
CA2801487A1 (en) | 2011-12-08 |
TW201201793A (en) | 2012-01-16 |
ES2612452T3 (es) | 2017-05-17 |
CN103038245A (zh) | 2013-04-10 |
EP2576585B8 (en) | 2016-12-21 |
WO2011153315A1 (en) | 2011-12-08 |
BR112012030818A2 (pt) | 2019-09-24 |
EA201270780A1 (ru) | 2013-04-30 |
US20120142707A1 (en) | 2012-06-07 |
JP2013527242A (ja) | 2013-06-27 |
CN103038245B (zh) | 2015-03-25 |
AR081637A1 (es) | 2012-10-10 |
EA022393B1 (ru) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012013703A (es) | Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih). | |
MX2012013628A (es) | Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih). | |
TN2013000321A1 (en) | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity | |
MX2013008359A (es) | Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana. | |
MX2014013089A (es) | Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih). | |
MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
MX2015010354A (es) | Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih). | |
AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
AU2012253759A8 (en) | Tricyclic sulfonamide compounds and methods of making and using same | |
MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
TN2012000428A1 (en) | Bisaryl-bonded aryltriazolones and use thereof | |
TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
GEP20186838B (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors | |
MX2011008634A (es) | Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia. | |
MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
EA201491531A1 (ru) | C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич | |
JO3122B1 (ar) | مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية | |
MX2015010003A (es) | Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih). | |
PH12015500062A1 (en) | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments | |
MY164842A (en) | Isoxazolidine derivatives | |
MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
JOP20170029B1 (ar) | C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1 | |
WO2012019428A8 (zh) | 二苯甲醇类衍生物、其制备方法及其在医药上的应用 | |
PH12018501640A1 (en) | C-3 and c-17 modified triterpenoids as hiv-1 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |